International Flavors & Fragrances(US:IFF)2026-02-27 22:16Financial Performance - In 2025, the company's sales decreased by 5% to $10.890 billion compared to $11.484 billion in 2024, but increased by 2% on a comparable currency neutral basis [191]. - The gross profit for 2025 was $3.938 billion, representing a decrease of $186 million or 5% from $4.124 billion in 2024, with a gross margin of 36.2% [193]. - The operating loss for 2025 was $382 million, compared to an operating profit of $766 million in 2024, marking a significant decline [194]. - Total net sales decreased to $10.890 billion in 2025, down 5.2% from $11.484 billion in 2024, impacted by business divestitures and currency fluctuations [201]. - Segment Adjusted Operating EBITDA decreased by 5% to $2.086 billion in 2025, with a 7% increase on a comparable currency neutral basis [218]. Sales by Segment - The Taste segment reported sales of $2.481 billion in 2025, a 2% increase from $2.428 billion in 2024, with a 4% increase on a comparable currency neutral basis [198]. - The Food Ingredients segment saw a sales decrease of $87 million, or 3%, to $3.278 billion in 2025, with a comparable currency neutral sales decrease of 3% [199]. - Health & Biosciences segment sales increased by $80 million, or 4%, to $2.283 billion in 2025, with a 3% increase on a comparable currency neutral basis [200]. - The Scent segment's sales increased by 2% to $2.479 billion in 2025, with a comparable currency neutral increase of 3% [196]. - Pharma Solutions sales decreased by $680 million, or 65%, to $369 million in 2025, with a 12% increase on a comparable currency neutral basis [203]. Expenses and Costs - Cost of sales decreased by $408 million to $6.952 billion, representing 63.8% of sales in 2025, compared to 64.1% in 2024 [204]. - Research and development (R&D) expenses increased by 3% to $694 million in 2025, representing 6.4% of sales [194]. - S&A expenses decreased by $161 million to $1.834 billion, representing 16.8% of sales in 2025, down from 17.4% in 2024 [206]. - R&D expenses increased by $23 million to $694 million, accounting for 6.4% of sales in 2025, up from 5.8% in 2024 [205]. Impairment Charges - The company recorded an impairment charge of $1.153 billion for the Food Ingredients reporting unit due to goodwill impairment following the segment reorganization [187]. - Impairment of goodwill was $1.153 billion in 2025, significantly higher than $64 million in 2024, related to the Food Ingredients and Pharma Solutions segments [209]. - A goodwill impairment charge of $1.153 billion was recorded for the Food Ingredients reporting unit as of January 1, 2025, leaving no goodwill remaining in that unit [289]. - In 2023, a goodwill impairment charge of $2.623 billion was recorded for the Nourish reporting unit due to its carrying value exceeding fair value [292]. - The company recorded a goodwill impairment charge of $64 million related to the Pharma Solutions disposal group for the year ended December 31, 2024 [291]. Cash Flow and Debt - Cash flows provided by operating activities in 2025 were $850 million, or 7.8% of sales, down from $1.070 billion, or 9.3% of sales, in 2024, primarily due to increased working capital and higher incentive compensation payouts [255]. - Cash flows provided by investing activities surged to $2.269 billion in 2025 from $326 million in 2024, driven by higher net proceeds from business divestitures [257]. - Cash flows used in financing activities increased to $3.091 billion in 2025 from $1.606 billion in 2024, mainly due to the purchase of Senior Notes for $2.0 billion [259]. - As of December 31, 2025, the company had total debt of approximately $6.026 billion, with net debt calculated at $5.436 billion [270]. - The net debt to credit adjusted EBITDA ratio was 2.59 to 1.0 as of December 31, 2025, indicating compliance with financial covenants [268]. Capital Expenditures and Future Outlook - Capital spending in 2026 is expected to be approximately 6% of sales, reflecting a re-prioritization of capital projects [258]. - The company had no outstanding borrowings under its $2 billion Revolving Credit Facility as of December 31, 2025, with available capacity remaining at $2 billion [266]. Tax and Fair Value Considerations - An income tax benefit of $360 million was recognized in 2025 related to the legal entity realignment project, which involved estimating the fair value of relevant legal entities [293]. - The estimated fair value of the Health & Biosciences reporting unit would decrease by 2% if the weighted average cost of capital increased by 50 basis points, potentially resulting in an impairment charge [290]. - The fair value of the company's EUR fixed rate debt was $935 million as of December 31, 2025, with an estimated change of approximately $94 million based on a hypothetical 10% fluctuation in foreign exchange rates [308]. - The fair value of the company's USD fixed rate debt was $4.053 billion as of December 31, 2025, with an estimated change of approximately $405 million based on a hypothetical 10% fluctuation in interest rates [308]. - The estimated fair value of foreign currency forward contracts would change by approximately $199 million based on a hypothetical 10% change in applicable exchange rates [306]. - The company actively monitors foreign currency exposures and employs hedging activities to mitigate the impact of exchange rate fluctuations [304].